Description
Recombinant Rat HER2/ErbB2 Protein (aa 4-656, His Tag) | PKSR030372 | Gentaur US, UK & Europe Disrtribition
Synonyms: Receptor tyrosine-protein kinase erbB-2; Epidermal growth factor receptor-related protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; p185erbB2; p185neu; CD340; ERBB2;ENV;ENVW;ERVWE1;HER-2;HER-2/neu;HER2;HERV-7q;HERV-W-ENV;HERV7Q;HERVW;HERVWENV;MLN 19;MLN19
Active Protein: N/A
Activity: A DNA sequence encoding the rat ErbB2 (AAH61863.1) extracellular domain (Met 4-Thr 656) was expressed, fused with a polyhistidine tag at the C-terminus.
Protein Construction: A DNA sequence encoding the rat ErbB2 (AAH61863.1) extracellular domain (Met 4-Thr 656) was expressed, fused with a polyhistidine tag at the C-terminus.
Fusion Tag: C-His
Species: Rat
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 71.3 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: N/A
